Current Guidelines on Antithrombotic Management in Patients Undergoing Gastrointestinal Endoscopy
| Autor: | M. Begawan Bestari, Laksono, Bayu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
lcsh:Internal medicine
Asia Anticoagulant Gastroenterology Anticoagulants Endoscopy Gastrointestinal United States Europe Antithrombotic Fibrinolytic Agents Practice Guidelines as Topic Antiplatelet Humans Gastrointestinal endoscopy lcsh:RC31-1245 Gastrointestinal Hemorrhage Platelet Aggregation Inhibitors Societies Medical |
| Zdroj: | Scopus-Elsevier Publons Acta Medica Indonesiana, Vol 51, Iss 1 (2019) |
| ISSN: | 0125-9326 |
| Popis: | Endoscopic procedure is commonly used to make diagnosis or therapy. Endoscopy has risk on the procedure or after the procedure. Patient with antithrombotic therapy, both antiplatelet and/or anticoagulant, for underlying diseases has higher risk for bleeding and thromboembolic events in this procedure. The physician should consider risk and benefit for adjusting the antithrombotic therapy, in addition to minimize bleeding and thromboembolic events. For low risk procedure, adjustments in antithrombotic therapy usually not necessarily needed. For high risk procedure, there are several adjustments based on the type of medication and patient’s condition in specific. European Society of Gastrointestinal Guidelines Endoscopy (ESGE) and British Society of Gastrointestinal (BSG); American Society of Gastrointestinal Endoscopy (ASGE); and lastly Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) have published guidelines to help physician to make decisions regarding antithrombotic therapy management during endoscopy. This article compares and contrasts the approach of each guideline, in design to help the decision-making process. However, each patient’s clinical condition may differ from one to another and should be considered carefully in making a final decision. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|